Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARICADE-DELAY trial of baricitinib to delay stage 3 type 1 diabetes
NL-OMON59958Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Baricitinib with Placebo (2 arms). Primary endpoint: Time from baseline to diagnosis of stage 3 type 1 diabetes. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
baricitinib
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON59958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59958.